Non-Human Primate (NHP) Application in Immunogenicity Profiling (Humoral & Cellular)

Are you facing unpredictable immunogenicity, high clinical failure rates due to anti-drug antibodies (ADA) or neutralizing antibodies (NAb), and challenges in T-cell monitoring for advanced therapies? Our NHP Immunogenicity Profiling Services help you de-risk your therapeutic development and accelerate regulatory submission through clinically predictive in vivo models and advanced humoral and cellular assay platforms.

NHP Models Deliver Crucial Translational Insights into Vector Safety and Immune Responses

Unpredictable human immune responses are the leading cause of late-stage failure for novel biologics and gene therapies. NHP models provide essential, high-fidelity translational data for comprehensive vector safety, biodistribution, and adaptive immune response profiling.

Get a Quote

Overview of NHP Applications

What Are Our Research Areas?

Immunogenicity profiling is the critical preclinical research field dedicated to evaluating a therapeutic candidate's potential to elicit an unwanted immune response. For advanced therapies, such as AAV gene vectors, CAR-T cells, and monoclonal antibodies, this research must assess two main components: humoral immunity (the formation of anti-drug or anti-vector antibodies, particularly neutralizing antibodies or NAbs) and cellular immunity (the activation and expansion of T cells, which can lead to vector clearance or cytokine-mediated toxicity). Accurate immunogenicity assessment in a highly translational model is essential to predict human safety and efficacy, particularly given the demonstrated risk of pre-existing antibodies in patient populations and the absolute necessity of evading adaptive immunity for durable efficacy.

Why Choose Us?

NHPs are the gold standard for immunogenicity profiling, offering unparalleled predictability for regulatory success.

Genetic/Immunological Similarities: NHPs share close genetic homology and a highly similar immune system structure (e.g., T-cell receptor repertoire, cytokine profiles) to humans, providing the most relevant immune response data outside of the clinic.
Clinical Translational Relevance: NHP models allow for clinically relevant dosing, administration routes (e.g., intra-venous, intrathecal), and complex sampling, generating data directly translatable to Phase I trial design.
Data Types Required for Regulatory Submissions: Agencies often mandate NHP data, especially for Advanced Therapy Medicinal Products like gene and cell therapies, to assess biodistribution, shedding, and immune-mediated clearance.
Complex Response Monitoring: NHPs facilitate the simultaneous longitudinal monitoring of both NAb titers and detailed cellular cytokine release, which is crucial for assessing potential Cytokine Release Syndrome (CRS) or immune-mediated vector destruction.

Key Applications

NHPs provide the comprehensive platform necessary to assess vector safety and predict immune-mediated failure in the clinical setting.

Pre-existing NAb Screening & Functional Profiling: NHPs are used to confirm vector-specific neutralizing antibody (NAb) activity and assess the potential for novel capsids to evade both humoral and T-cell responses, predicting initial therapeutic success.
Modeling Cytokine Release Syndrome (CRS) & T-Cell Profiling: NHPs are essential for predicting off-target toxicity and dose-dependent systemic inflammation (CRS) for CAR-T and other cell therapies via advanced cytokine/chemokine profiling.
Re-Dosing & Durability Studies Adaptive Immunity Clearance Kinetics: NHPs allow for longitudinal monitoring of Anti-Drug/Anti-Vector Antibodies (ADA/AVA) and cytotoxic T-lymphocyte (CTL) responses following the initial dose, determining the feasibility and safety margin for subsequent therapeutic administrations.
Biologic & Vaccine Testing PK/PD and Immunogenicity Correlation: NHPs are used to establish a clear link between drug exposure (PK), target engagement (PD), and the generation of unwanted ADA, providing critical data to select optimal dosing regimens.

How Do Creative Biolabs Support Your Projects?

Creative Biolabs offers an integrated suite of services designed to generate the high-quality NHP data required for successful regulatory submissions.

Service Capability	Corresponding Application Area
ADA & Neutralizing Antibody (NAb) Assays	Measures pre-existing and induced anti-vector/anti-drug antibodies.
Advanced Therapy Safety (Gene/Cell Therapy)	Full safety profiling including clinical observations and immunotoxicity endpoints.
Cytokine/Chemokine Multiplex (Luminex, Simoa)	Used for detailed monitoring of systemic inflammation and T-cell-mediated responses.
Gene Therapy Models (AAV, Lentivirus)	Longitudinal monitoring of vector copy number in target tissues.

Translational Impact

Leveraging NHP models for immunogenicity profiling is a direct strategy for reducing the risk of expensive clinical failure. The close physiological relevance of NHP data provides more reliable early proof of concept, enabling the early detection of immune responses and unexpected toxicities. This data is not just supportive; NHP biodistribution, shedding, and safety pharmacology data are often required for advanced therapy IND submissions. By establishing a robust non-clinical safety profile in NHPs, we help you streamline the path to the clinic.

Frequently Asked Questions

Q: How does Creative Biolabs ensure the data quality and translational relevance of the immunogenicity assays?

A: Our platforms utilize customized assay development for both NAb and ADA quantification, often using state-of-the-art technologies for high sensitivity and multiplexing. Furthermore, all data is generated from fully characterized NHP cohorts, maximizing the clinical predictability of the results.

Q: What sample specifics are required, and what is the stability for cellular immunogenicity analysis?

A: Cellular immunity relies on freshly isolated PBMCs for accurate results. We provide dedicated Custom Collection Services to ensure optimal sample viability and stability from collection to analysis, guaranteeing the quality of complex assays like flow cytometry.

Q: What is the typical turnaround time for a complete NHP immunogenicity and safety package?

A: Study duration is highly dependent on the dose regimen. However, we commit to rapid sample processing and analysis. Once the study phase is complete, final integrated bioanalytical reports are typically delivered within 8–12 weeks, providing actionable data for your next development phase.

Q: How do NHP immunogenicity models compare to transgenic humanized mouse models for T-cell response prediction?

A: While humanized mouse models are useful for initial screening, NHPs are essential for regulatory relevance and complex T-cell epitope mapping due to their intact, highly relevant MHC and complete immune system repertoire. Our NHP platform provides a higher fidelity prediction of clinical T-cell mediated toxicity.

Contact Us

Creative Biolabs provides the integrated NHP models, advanced bioanalytical platforms, and regulatory expertise to decisively profile both the humoral and cellular immunogenicity of your advanced therapeutic candidate. To discuss your project's specific requirements for NHP immunogenicity profiling and to request a detailed quotation, please reach out to our team.